Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pharmaco-economic Study of a New Medical Device Performed From the Perspective of the Hospital (Caphosol)

This study has been completed.
Jazz Pharmaceuticals
Information provided by (Responsible Party):
Nantes University Hospital Identifier:
First received: August 26, 2011
Last updated: May 2, 2016
Last verified: April 2016
The purpose of the study is to determine whether the use of mouthwashes Caphosol ™ in addition to standard oral care (strategy A) is cost-effective in the prevention and treatment of severe mucositis in adult patients with auto or allograft packaging without ICT versus mouthwashes standard bicarbonates with an antiseptic (strategy B).

Condition Intervention Phase
Hematologic Disease
Device: Caphosol
Drug: Bicarbonate de sodium
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Pharmaco-economic Cost-effective Prospective Randomized Trial Evaluating the Open Interest Caphosol ® Mouthwashes in the Prevention and Treatment of Severe Oral Mucositis in Patients Receiving High-dose Chemotherapy in Hematology

Resource links provided by NLM:

Further study details as provided by Nantes University Hospital:

Primary Outcome Measures:
  • assess the cost-effectiveness ratio is the number of days with severe mucositis won. [ Time Frame: up to 28 days ]

Secondary Outcome Measures:
  • The number of days without medication morphine won [ Time Frame: up to 28 days ]
  • Aggregate saving medicines prescribed Supportive [ Time Frame: up to 28 days ]
  • The incidence of mucositis [ Time Frame: up to 28 days ]
  • The intensity of pain assessed with a visual analogue scale [ Time Frame: up to 28 days ]
  • The cumulative dose of morphine administered and the number of days of treatment, [ Time Frame: 28 days ]
  • The duration of febrile neutropenia [ Time Frame: up to 28 days ]
  • - The incidence and duration of treatment of anti-infective and antifungal [ Time Frame: 28 jours ]
  • The incidence of total parenteral nutrition [ Time Frame: up to 28 days ]
  • - The duration of Release aplasia (ANC> 500/mm3), [ Time Frame: up to 28 days ]
  • The duration of the hospitalization [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 28 days ]
  • The severity of mucositis [ Time Frame: up to 28 days ]
  • The duration of pain assessed with a visual analogue scale, [ Time Frame: up to 28 days ]

Enrollment: 92
Study Start Date: April 2011
Study Completion Date: April 2014
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Caphosol Device: Caphosol

The Caphosol ™ is a recently launched medical in France (2009). (source: laboratory EUSA Pharma ®)

The product is an aqueous solution for mouthwash that comes in the form of a hyper-saturated mixture of calcium phosphate at neutral pH to reconstitute immediately before use.

Each patient randomized to the treatment arms in the study will receive daily at least 4 (maximum 10) mouthwash Caphosol ™.

The treatments are to begin preventive J1 to chemotherapy and continued until out of aplasia (ANC> 500/mm3), and / or mucositis grade 0.

Active Comparator: Référence
•Bicarbonate de sodium à 1.4% Biosedra Versylène® or PAROEX® :
Drug: Bicarbonate de sodium

Treatment of the early start on the day of conditioning and stop when the ANC> 500/mm3 and / or mucositis grade zero, provisional date of bone exceeded.

Versylène: Method of administration: gargle made with a minute from 15 to 30 mL, 2-5 times a day, alternating with PAROEX ®.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients > 18 years

Patient receiving:

  • Conditioning of autologous bone marrow transplantation by high dose melphalan (HD) as part of the management of myeloma or BEAM in lymphoma.
  • A conditioning allogeneic bone marrow transplantation with reduced or intermediate busulfan IV
  • Patients belong to a schema of social security, having signed the written informed consent.

Exclusion Criteria:

  • patients:
  • To receive or have received KGF
  • With previous history of RT with the exception of patients who received spinal analgesic therapy in the treatment of myeloma
  • Unable or unwilling to complete the self assessment questionnaire
  • With previous history of allergy to any component of the products under consideration
  • Minor
  • Adults under guardianship
  • Pregnant women
  • Patients who have not signed the consent form
  • Creation of mouthwash out of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01426295

Nantes Universty Hospital
Nantes, France, 44200
Sponsors and Collaborators
Nantes University Hospital
Jazz Pharmaceuticals
Principal Investigator: Thomas Gastinne, M D Nantes University Hospital
  More Information

Responsible Party: Nantes University Hospital Identifier: NCT01426295     History of Changes
Other Study ID Numbers: BRD/10/06-C
Study First Received: August 26, 2011
Last Updated: May 2, 2016

Keywords provided by Nantes University Hospital:
hematologic disease candidates for autologous or allogeneic bone marrow

Additional relevant MeSH terms:
Hematologic Diseases processed this record on April 28, 2017